Innate Pharma S.A. (IPHA)

Innate Pharma Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Innate Pharma stock has a target of 11, which predicts a 435.28% increase from the current stock price of 2.06.

Price Target: $11 (+435.28%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$11	$11	$11	$11
Change	+435.28%	+435.28%	+435.28%	+435.28%

* Price targets were last updated on Apr 24, 2025.

Analyst Ratings

According to 1 stock analyst, the rating for Innate Pharma is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Apr '25	May '25	Jun '25	Jul '25	Aug '25	Sep '25
Strong Buy	1	1	1	1	1	1
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	1	1	1	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $12 → $11	Strong Buy	Reiterates	$12 → $11	+435.28%	Apr 24, 2025
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $12	Strong Buy	Reiterates	$12	+459.61%	Mar 28, 2025
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $12	Strong Buy	Reiterates	$12	+459.61%	Feb 6, 2025
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $12	Strong Buy	Reiterates	$12	+459.61%	Jan 17, 2025
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $12	Strong Buy	Reiterates	$12	+459.61%	Dec 9, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

90.74M

Increased by 350.96%

from 20.12M

Revenue Next Year

120.61M

Increased by 32.92%

from 90.74M

EPS This Year

0.37

from -0.61

EPS Next Year

0.26

Decreased by -28.28%

from 0.37

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	69.77M	24.70M	57.67M	61.64M	20.12M	90.74M	120.61M
Revenue Growth	-18.35%	-64.60%	133.47%	6.88%	-67.36%	350.96%	32.92%
EPS	-0.81	-0.66	-0.73	-0.09	-0.61	0.37	0.26
EPS Growth	-	-	-	-	-	-	-28.28%
Forward PE	-	-	-	-	-	4.73	6.59
No. Analysts	-	-	-	-	-	6	5

Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	193.2M	302.4M
Avg	90.7M	120.6M
Low	12.7M	6.6M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	860.2%	233.3%
Avg	351.0%	32.9%
Low	-37.0%	-92.7%

EPS Forecast

EPS	2025	2026	2027
High	1.41	1.88
Avg	0.37	0.26
Low	-0.74	-0.74

EPS Growth

EPS Growth	2025	2026	2027
High	-	413.3%
Avg	-	-28.3%
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.